Ageing Bone Cells Lose a Key Epigenetic Brake, Driving Osteoporosis

Bone is not the inert scaffold it appears to be. Throughout life, it is continuously dismantled and rebuilt by two opposing cell populations: osteoclasts, which resorb old bone, and osteoblasts, which lay down new matrix. Ageing tips this balance toward resorption, and the result is osteoporosis—a disease of reduced bone mineral density, deteriorated microarchitecture and mounting fracture risk that affects roughly a third of people over 65, with women bearing the brunt at 51.6 percent prevalence. A new study published in the Journal of Cellular and Molecular Medicine now traces a crucial part of that decline to a single epigenetic switch inside osteoblasts, revealing how the loss of one chromatin-modifying enzyme can push bone-forming cells into a senescent, inflammatory state that accelerates skeletal ageing.

The enzyme in question is protein arginine methyltransferase 6, or Prmt6, the only known writer of a histone mark called H3R2me2a—asymmetric dimethylation of arginine 2 on histone H3. This mark is generally associated with transcriptional repression and is mutually exclusive with the active H3K4 methylation marks, meaning that where H3R2me2a sits, genes tend to stay quiet. In cancer biology, Prmt6 has already earned a reputation as a brake on cellular senescence: by depositing H3R2me2a near genes such as p53 and p21, it suppresses the expression of senescence programmes and keeps cells proliferating. Whether the same anti-ageing mechanism operated in bone, however, had never been tested—until a team working under protocols approved by the Tongji University Committee for the Protection and Use of Laboratory Animals set out to interrogate it in mice.

The researchers built their case on two complementary models of osteoblast ageing. In the first, they exposed cultured newborn mouse skull-derived osteoblasts to 200 micromolar hydrogen peroxide for two hours, inducing oxidative-stress-driven senescence. In the second, they simply passaged the cells repeatedly, letting replicative exhaustion accumulate naturally. Both models worked as intended: western blots and quantitative PCR showed rising levels of the senescence markers P16 and P21, immunofluorescence confirmed their intracellular accumulation, and senescence-associated beta-galactosidase staining revealed a growing fraction of blue-stained, senescent cells. Crucially, as senescence deepened, Prmt6 and its H3R2me2a mark faded from the cells at both the mRNA and protein levels—the first hint that this epigenetic system weakens as osteoblasts age.

To test causality rather than mere correlation, the team isolated osteoblasts from Prmt6 knockout mice. Removing the enzyme crashed H3R2me2a levels, and the senescence programme surged: P16 and P21 climbed, beta-galactosidase-positive cells multiplied, and the expression of osteogenic markers—Alp, Ocn and the master transcription factor Runx2—fell significantly. In practical terms, bone-forming cells without Prmt6 not only looked old; they lost their ability to mature and mineralise matrix. Transcriptome-wide RNA sequencing reinforced the picture. Principal component analysis cleanly separated knockout cells from controls along the first principal component, and differential expression analysis identified 2,478 altered genes, 682 upregulated and 1,796 downregulated. Gene ontology and KEGG pathway enrichment pointed to a triad of disruption: suppressed ossification and collagen matrix assembly, enhanced immune cell migration and TNF-alpha production, and altered PI3K-Akt and Rap1 signalling pathways known to govern osteoblast survival and adhesion.

Among all these changes, one innate immune gene stood out. Cross-referencing the differentially expressed genes against Sting-pathway members yielded two candidates, Sting and Nfkbia, but only Sting was consistently and stably regulated by Prmt6 loss. Sting—the stimulator of interferon genes—is the central adaptor of the cGAS-STING pathway, which normally senses cytoplasmic DNA and launches a type I interferon response. In recent years, the pathway has been implicated in ageing far beyond its anti-infective origins: aberrant Sting activation drives chronic low-grade inflammation, senescence-associated secretory phenotype expression and, in the skeleton, mitochondrial dysfunction through the HK2-VDAC1 axis. In the knockout osteoblasts, Sting mRNA and protein rose sharply, and the same elevation appeared in both chemically induced and replicative senescence models.

The functional test followed: when the researchers knocked out Sting, senescence markers P16 and P21 dropped, the antioxidant enzyme Gpx4 increased, beta-galactosidase-positive cells declined, and the osteogenic markers Alp, Ocn and Runx2 rebounded. In other words, silencing Sting did not merely correlate with healthier osteoblasts—it partially rescued them from senescence and restored differentiation capacity. Sting, it appeared, was not an innocent bystander in the ageing bone but an active driver of the senescent state that Prmt6 loss had unleashed.

Downstream of Sting, the trail led to Ifitm3, an interferon-induced transmembrane protein better known for blocking enveloped viruses such as influenza and dengue by stiffening endosomal and lysosomal membranes. Ifitm3 is a classic interferon-stimulated gene, so when Sting signalling fires, Ifitm3 expression follows. The new data confirmed the dependency: Sting knockdown reduced Ifitm3 at every level measured. And like Sting, Ifitm3 climbed in senescent osteoblasts, in Prmt6-deficient cells, and in the femurs of naturally ageing mice, while Ifitm3 knockout reduced P16 and P21, lowered beta-galactosidase positivity, and boosted osteogenic gene expression. The authors suggest that by altering membrane fluidity, promoting lysosomal activity and disrupting autophagic flux, Ifitm3 may be one of the molecular hands that physically push an osteoblast into senescence—though they caution that the precise effector mechanisms remain to be disentangled.

The animal data tied the cellular story to real bone loss. Using micro-CT scanning at 25-micrometre resolution on femurs from mice aged 2, 12 and 24 months, the team documented the expected march of osteoporosis: trabecular number, bone volume fraction, bone surface density and trabecular thickness all fell with age, while trabecular separation widened. Haematoxylin and eosin staining showed coarsened trabecular edges, enlarged marrow spaces and microfractures. Superimposed on this structural decay was the molecular signature: Prmt6 and H3R2me2a declined progressively in femoral tissue, while Sting and Ifitm3 rose—mirroring exactly the gradients seen in the culture dish.

The authors are candid about the limits of the work. The chromatin accessibility changes at the Sting locus following H3R2me2a loss are currently correlative; direct causality, and the possibility that Prmt6 acts through H3R2me2a-independent routes, await rescue experiments. Likewise, whether Ifitm3 directly executes senescence or merely permits it remains unresolved, with experiments involving cholesterol-binding mutants, lysosomal pH modulators and live autophagic-flux monitoring now under way. Even so, the study assembles the first integrated link between a Prmt6-mediated histone modification, the Sting innate immune pathway and osteoblast senescence in vivo, and it reframes age-related osteoporosis as a disease in which the bone-forming compartment loses its epigenetic defences rather than one driven simply by overactive osteoclasts.

If the axis holds up, the therapeutic implications are considerable. The open chromatin state of the Sting locus could serve as a biomarker of osteoblast ageing, and drugs that restrain Sting signalling or restore H3R2me2a deposition might delay or partially reverse bone loss in the elderly. With population ageing intensifying worldwide and osteoporosis already a leading cause of disability and fracture-related mortality, an epigenetic handle on the disease would be a welcome addition to a therapeutic landscape dominated for decades by antiresorptive agents. The road from mouse femurs to human clinics is long, and the authors themselves flag that long-term efficacy and safety of any such epigenetic strategy must be systematically evaluated—but the mapping of this pathway marks a genuine step forward in understanding why our bones grow old.

Subject of Research: Epigenetic regulation of osteoblast senescence in age-related osteoporosis via the Prmt6/H3R2me2a/Sting/Ifitm3 pathway

Article Title: Prmt6 Deficiency Drives Osteoblast Senescence Promoting Age‐Related Osteoporosis via Epigenetic Remodelling of the H3R2me2a/Sting/Ifitm3 Pathway

Article References: Wang, Y., Ge, X., Chang, S., Wang, D., Xu, K., Xu, H., Liu, X., & Wang, S. (2026). Prmt6 Deficiency Drives Osteoblast Senescence Promoting Age‐Related Osteoporosis via Epigenetic Remodelling of the H3R2me2a /Sting/Ifitm3 Pathway. Journal of Cellular and Molecular Medicine, 30(18), Article e71308. https://doi.org/10.1111/jcmm.71308

Image Credits: AI Generated

DOI: 10.1111/jcmm.71308

Keywords: osteoporosis, osteoblast senescence, Prmt6, H3R2me2a, STING, Ifitm3, epigenetics, cellular ageing, bone metabolism, innate immunity, chromatin remodelling, ageing